Retired Chairman And Ceo
Hemoshear Therapeutics, Inc.
Charlottesville, Virginia
HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. Our proprietary drug discovery platform, REVEAL-TX™, enables us to create best-in-class biological human disease models to uncover and explain the underlying mechanisms of disease, translate those discoveries into drug candidates, and predict which drug candidates will treat patients successfully. Our lead asset, HST5040, is currently in a phase 2 clinical study to treat methylmalonic and propionic academia, which are severe rare inherited metabolic disorders with no approved treatment. HemoShear has several addition drug discovery programs for rare inherited diseases at earlier stages in its pipeline, as well as drug discovery partnerships in nonalcoholic steatohepatitis (NASH) with Takeda, and in gout with Horizon Therapeutics.